Annovis Bio regains NYSE listing compliance

Annovis Bio

Annovis Bio

ANVS

0.00
  • Annovis Bio regained compliance with NYSE continued listing standards.
  • The NYSE flagged the stock on March 26, 2025, citing market capitalization below USD 50 million and stockholders’ equity below USD 50 million.
  • An 18-month cure period was granted in June 2025; the company returned to compliance within 12 months.
  • The common stock will remain listed on the NYSE under ticker ANVS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9726306) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.